Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Key Points
Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance.
Viking Therapeutics and Abivax are developing promising candidates.
Both could release important data readouts within the next 18 months.
- 10 stocks we like better than Viking Therapeutics ›
Eli Lilly (NYSE: LLY) has crushed the market over the past decade, largely thanks to breakthroughs within its core therapeutic area. Some might think it's too late to invest in the stock. Eli Lilly is now the largest healthcare stock in the world, with a market cap that at one point climbed above $1 trillion.
While I think Eli Lilly remains a buy, if you think you missed out, it's worth considering smaller stocks that aim to emulate its success. Here are two: Viking Therapeutics (NASDAQ: VKTX) and Abivax (NASDAQ: ABVX).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
1. Viking Therapeutics
Viking Therapeutics is following in Eli Lilly's footsteps by trying to develop effective weight loss medicines. The biotech company's leading candidate, VK2735, is a dual GLP-1/GIP agonist (it mimics the action of these two gut hormones), just like Eli Lilly's Zepbound. VK2735 is undergoing a phase 3 study for which we should see results by next year.
Viking Therapeutics is also developing an oral version of this therapy, while testing different ways to help patients keep the weight off after losing it, using various dosing schedules (daily, weekly, monthly) for both the oral and subcutaneous formulations.
What makes this stock somewhat promising is that Viking Therapeutics' phase 2 results for VK2735 were strong, and the company could differentiate itself with its oral and subcutaneous formulations of the medicine under development. However, Viking Therapeutics is also risky, as clinical setbacks will sink its share price.
2. Abivax
Abivax's leading candidate, obefazimod, could enter a crowded market. It is being developed as a potential treatment for ulcerative colitis (UC) and other autoimmune conditions. Many drugmakers, including Eli Lilly, market medicines in this area. However, obefazimod works differently from most. It could help control UC symptoms and help patients achieve remission without suppressing immune system activity.
That's how some immunosuppressant drugs work, hence their name. However, reducing immune system activity has drawbacks, such as making patients more susceptible to certain diseases.
Obefazimod could address this problem while still demonstrating strong efficacy, as it has so far in clinical trials. Abivax is currently running a maintenance study of obefazimod in UC patients, with results planned for announcement during the second quarter.
If the medicine can demonstrate sustained efficacy, Abivax's shares could jump. And eventually, obefazimod could generate over $1 billion in annual sales. The same caveats apply, though: Abivax is a high-risk, potentially high-reward play, as a clinical setback here will crush the stock.
Should you buy stock in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,362!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,164,984!*
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 10, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Viking Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
